Open access
Aug 2026
Bispecific Antibodies Targeting PD-1/PD-L1 and VEGF in Non-Small Cell Lung Cancer
Mature randomized survival data, longer-term safety assessment, and biomarker development are needed to define optimal patient selection and the clinical role of PD-(L)1/VEGF bispecific antibodies in NSCLC.
Aleena Kuriakose, Salem Gogah, E. Beleva
· Journal of Clinical Question... · 0 citations